Ann: Change of Director's Interest Notice, page-62

Article??? You need to DYOR and clearly you haven't, ResAppDx has already received regulatory approval for asthma and COPD (which RSH doesn't but there was an ASX announcement of a clinical study tested against the stethoscope for COPD management a few years ago which went totally silent, you should ask @lucasq and @Yenom23 about this????) exacerbation which used clinical studies data tested against current clinician standards. Wheezo has received regulatory approval many years ago under multiple version using clinical trial data tested against just the stethoscope and not the current physician standard, hence, the new CEO mentioned about doing clinical studies against current physician standard and I couldn't find any pre-clinical studies for this, there were for RAP so I would be surprise if the clinical trial for chronic COPD management screening will show different result to these pre-clinical studies which is understandable since the algorithm is an extension of ResAppDx that has been clinically proven to detect asthma and COPD exacerbation. Also chronic asthma and COPD patients don't need to use an additional wearable hardware provided by RAP which was designed by OSI System and is undergoing CE Mark certification to use this product if they don't want to, they can use their smartphone which this clinical trials will use as the regulatory approval will be against the microphone but Wheezo require the $300 hardware that looks like an egg for chronic respiratory management for just asthma.